-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the website of the State Food and Drug Administration, the State Food and Drug Administration recently issued the "Notice on 16 Batches of Drugs Not Complying with the Regulations (No.
36 of 2021)" (hereinafter referred to as the "Notice")
.
The "Notice" stated that 16 batches of drugs including compound clotrimazole cream produced by 14 companies including Hebei Jiuzheng Pharmaceutical Co.
, Ltd.
were not in compliance with the regulations after being inspected by 8 drug inspection institutions including Anhui Food and Drug Inspection and Research Institute.
.
The relevant situation is now announced as follows:
36 of 2021)" (hereinafter referred to as the "Notice")
.
The "Notice" stated that 16 batches of drugs including compound clotrimazole cream produced by 14 companies including Hebei Jiuzheng Pharmaceutical Co.
, Ltd.
were not in compliance with the regulations after being inspected by 8 drug inspection institutions including Anhui Food and Drug Inspection and Research Institute.
.
The relevant situation is now announced as follows:
After inspection by Anhui Food and Drug Inspection and Research Institute, it was labeled as 1 batch of compound clotrimazole cream produced by Hebei Jiuzheng Pharmaceutical Co.
, Ltd.
which did not meet the requirements, and the non-compliant items were microbiological limits; labeled as Shandong Boshan Pharmaceutical Co.
, Ltd.
One batch of compound clotrimazole cream produced does not meet the regulations, and the items that do not meet the regulations are the filling quantity
.
, Ltd.
which did not meet the requirements, and the non-compliant items were microbiological limits; labeled as Shandong Boshan Pharmaceutical Co.
, Ltd.
One batch of compound clotrimazole cream produced does not meet the regulations, and the items that do not meet the regulations are the filling quantity
.
After inspection by Shanxi Provincial Food and Drug Inspection Institute, it is indicated that the entrusting party is Shanxi Tianzhi Pharmaceutical Co.
, Ltd.
, and the trustee is Chongqing Tianzhi Pharmaceutical Co.
, Ltd.
The first batch of Gucining capsules does not meet the requirements, and the non-compliant items are moisture
.
, Ltd.
, and the trustee is Chongqing Tianzhi Pharmaceutical Co.
, Ltd.
The first batch of Gucining capsules does not meet the requirements, and the non-compliant items are moisture
.
After inspection by Yunnan Food and Drug Supervision and Inspection Institute, the three batches of joint pain relief ointment produced by Jiangsu Baiyi Pharmaceutical Co.
, Ltd.
and Jiangxi Ji'an Sanli Pharmaceutical Co.
, Ltd.
were not in compliance with the regulations, and the items that did not meet the regulations were content determination
.
, Ltd.
and Jiangxi Ji'an Sanli Pharmaceutical Co.
, Ltd.
were not in compliance with the regulations, and the items that did not meet the regulations were content determination
.
A batch of Huanglian Shangqing Pills produced by Sichuan Qiyun Pharmaceutical Co.
, Ltd.
was not in compliance with the regulations after inspection by the Hunan Institute of Drug Inspection (Hunan Pharmaceutical Excipients Inspection and Testing Center)
.
The items that did not meet the regulations were the difference in filling quantity .
, Ltd.
was not in compliance with the regulations after inspection by the Hunan Institute of Drug Inspection (Hunan Pharmaceutical Excipients Inspection and Testing Center)
.
The items that did not meet the regulations were the difference in filling quantity .
After inspection by the Tibet Autonomous Region Food and Drug Inspection and Research Institute, a batch of Keteling capsules produced by Yili Pharmaceutical Co.
, Ltd.
were not in compliance with the regulations, and the non-compliance items were microbiological limits
.
, Ltd.
were not in compliance with the regulations, and the non-compliance items were microbiological limits
.
After inspection by Wuhan Institute of Drug and Medical Device Inspection, a batch of Jiawei Huoxiang Zhengqi Pills produced by Guangzhou Yuehua Pharmaceutical Co.
, Ltd.
is not in compliance with the regulations, and the items that do not meet the regulations are identified
.
, Ltd.
is not in compliance with the regulations, and the items that do not meet the regulations are identified
.
After inspection by China National Institute for Food and Drug Control, the three batches of argentea produced by Anhui Jiancheng Chinese Medicine Decoction Pieces Co.
, Ltd.
, Anhui Xintai Pharmaceutical Co.
, Ltd.
, and Chengdu Ji'ankang Pharmaceutical Co.
, Ltd.
did not meet the requirements and did not meet the requirements.
For traits
.
, Ltd.
, Anhui Xintai Pharmaceutical Co.
, Ltd.
, and Chengdu Ji'ankang Pharmaceutical Co.
, Ltd.
did not meet the requirements and did not meet the requirements.
For traits
.
According to the inspection by Gansu Provincial Institute of Drug Inspection, the 2 batches of Bupleurum spp.
produced by Chongqing Zhongmiao Pharmaceutical Co.
, Ltd.
are not in compliance with the regulations, and the non-compliance items are traits; and the batch is labeled as 1 batch produced by Guangxi Yulin Tailong Chinese Medicine Decoction Pieces Co.
Sub-Bupleurum (North Bupleurum) does not meet the requirements, and the items that do not meet the requirements are traits; a batch of Bupleurum (North Bupleurum) labeled as Sichuan Renhe Chinese Medicine Decoction Pieces Co.
, Ltd.
does not meet the requirements, and the items that do not meet the requirements are impurities
.
produced by Chongqing Zhongmiao Pharmaceutical Co.
, Ltd.
are not in compliance with the regulations, and the non-compliance items are traits; and the batch is labeled as 1 batch produced by Guangxi Yulin Tailong Chinese Medicine Decoction Pieces Co.
Sub-Bupleurum (North Bupleurum) does not meet the requirements, and the items that do not meet the requirements are traits; a batch of Bupleurum (North Bupleurum) labeled as Sichuan Renhe Chinese Medicine Decoction Pieces Co.
, Ltd.
does not meet the requirements, and the items that do not meet the requirements are impurities
.
The "Notice" stated that for the above-mentioned non-compliant drugs, the drug supervision and administration department has required relevant enterprises and units to take risk control measures such as suspension of sales and use, recalls, and investigations into the reasons for non-compliance and effective rectification
.
.
State Drug Administration asked the relevant provincial drug administration department according to "People's Republic of China Drug Administration Law", the organization of these enterprises and units of production and sales of fake medicines of inferior quality products illegal investigation, the results of the investigation public in accordance with regulations
.
.
According to the website of the State Food and Drug Administration, the State Food and Drug Administration recently issued the "Notice on 16 Batches of Drugs Not Complying with the Regulations (No.
36 of 2021)" (hereinafter referred to as the "Notice")
.
The "Notice" stated that 16 batches of drugs including compound clotrimazole cream produced by 14 companies including Hebei Jiuzheng Pharmaceutical Co.
, Ltd.
were not in compliance with the regulations after being inspected by 8 drug inspection institutions including Anhui Food and Drug Inspection and Research Institute.
.
The relevant situation is now announced as follows:
36 of 2021)" (hereinafter referred to as the "Notice")
.
The "Notice" stated that 16 batches of drugs including compound clotrimazole cream produced by 14 companies including Hebei Jiuzheng Pharmaceutical Co.
, Ltd.
were not in compliance with the regulations after being inspected by 8 drug inspection institutions including Anhui Food and Drug Inspection and Research Institute.
.
The relevant situation is now announced as follows:
After inspection by Anhui Food and Drug Inspection and Research Institute, it was labeled as 1 batch of compound clotrimazole cream produced by Hebei Jiuzheng Pharmaceutical Co.
, Ltd.
which did not meet the requirements, and the non-compliant items were microbiological limits; labeled as Shandong Boshan Pharmaceutical Co.
, Ltd.
One batch of compound clotrimazole cream produced does not meet the regulations, and the items that do not meet the regulations are the filling quantity
.
, Ltd.
which did not meet the requirements, and the non-compliant items were microbiological limits; labeled as Shandong Boshan Pharmaceutical Co.
, Ltd.
One batch of compound clotrimazole cream produced does not meet the regulations, and the items that do not meet the regulations are the filling quantity
.
After inspection by Shanxi Provincial Food and Drug Inspection Institute, it is indicated that the entrusting party is Shanxi Tianzhi Pharmaceutical Co.
, Ltd.
, and the trustee is Chongqing Tianzhi Pharmaceutical Co.
, Ltd.
The first batch of Gucining capsules does not meet the requirements, and the non-compliant items are moisture
.
, Ltd.
, and the trustee is Chongqing Tianzhi Pharmaceutical Co.
, Ltd.
The first batch of Gucining capsules does not meet the requirements, and the non-compliant items are moisture
.
After inspection by Yunnan Food and Drug Supervision and Inspection Institute, the three batches of joint pain relief ointment produced by Jiangsu Baiyi Pharmaceutical Co.
, Ltd.
and Jiangxi Ji'an Sanli Pharmaceutical Co.
, Ltd.
were not in compliance with the regulations, and the items that did not meet the regulations were content determination
.
, Ltd.
and Jiangxi Ji'an Sanli Pharmaceutical Co.
, Ltd.
were not in compliance with the regulations, and the items that did not meet the regulations were content determination
.
A batch of Huanglian Shangqing Pills produced by Sichuan Qiyun Pharmaceutical Co.
, Ltd.
was not in compliance with the regulations after inspection by the Hunan Institute of Drug Inspection (Hunan Pharmaceutical Excipients Inspection and Testing Center)
.
The items that did not meet the regulations were the difference in filling quantity .
, Ltd.
was not in compliance with the regulations after inspection by the Hunan Institute of Drug Inspection (Hunan Pharmaceutical Excipients Inspection and Testing Center)
.
The items that did not meet the regulations were the difference in filling quantity .
After inspection by the Tibet Autonomous Region Food and Drug Inspection and Research Institute, a batch of Keteling capsules produced by Yili Pharmaceutical Co.
, Ltd.
were not in compliance with the regulations, and the non-compliance items were microbiological limits
.
, Ltd.
were not in compliance with the regulations, and the non-compliance items were microbiological limits
.
After inspection by Wuhan Institute of Drug and Medical Device Inspection, a batch of Jiawei Huoxiang Zhengqi Pills produced by Guangzhou Yuehua Pharmaceutical Co.
, Ltd.
is not in compliance with the regulations, and the items that do not meet the regulations are identified
.
, Ltd.
is not in compliance with the regulations, and the items that do not meet the regulations are identified
.
After inspection by China National Institute for Food and Drug Control, the three batches of argentea produced by Anhui Jiancheng Chinese Medicine Decoction Pieces Co.
, Ltd.
, Anhui Xintai Pharmaceutical Co.
, Ltd.
, and Chengdu Ji'ankang Pharmaceutical Co.
, Ltd.
did not meet the requirements and did not meet the requirements.
For traits
.
, Ltd.
, Anhui Xintai Pharmaceutical Co.
, Ltd.
, and Chengdu Ji'ankang Pharmaceutical Co.
, Ltd.
did not meet the requirements and did not meet the requirements.
For traits
.
According to the inspection by Gansu Provincial Institute of Drug Inspection, the 2 batches of Bupleurum spp.
produced by Chongqing Zhongmiao Pharmaceutical Co.
, Ltd.
are not in compliance with the regulations, and the non-compliance items are traits; and the batch is labeled as 1 batch produced by Guangxi Yulin Tailong Chinese Medicine Decoction Pieces Co.
Sub-Bupleurum (North Bupleurum) does not meet the requirements, and the items that do not meet the requirements are traits; a batch of Bupleurum (North Bupleurum) labeled as Sichuan Renhe Chinese Medicine Decoction Pieces Co.
, Ltd.
does not meet the requirements, and the items that do not meet the requirements are impurities
.
produced by Chongqing Zhongmiao Pharmaceutical Co.
, Ltd.
are not in compliance with the regulations, and the non-compliance items are traits; and the batch is labeled as 1 batch produced by Guangxi Yulin Tailong Chinese Medicine Decoction Pieces Co.
Sub-Bupleurum (North Bupleurum) does not meet the requirements, and the items that do not meet the requirements are traits; a batch of Bupleurum (North Bupleurum) labeled as Sichuan Renhe Chinese Medicine Decoction Pieces Co.
, Ltd.
does not meet the requirements, and the items that do not meet the requirements are impurities
.
The "Notice" stated that for the above-mentioned non-compliant drugs, the drug supervision and administration department has required relevant enterprises and units to take risk control measures such as suspension of sales and use, recalls, and investigations into the reasons for non-compliance and effective rectification
.
.
State Drug Administration asked the relevant provincial drug administration department according to "People's Republic of China Drug Administration Law", the organization of these enterprises and units of production and sales of fake medicines of inferior quality products illegal investigation, the results of the investigation public in accordance with regulations
.
.
According to the website of the State Food and Drug Administration, the State Food and Drug Administration recently issued the "Notice on 16 Batches of Drugs Not Complying with the Regulations (No.
36 of 2021)" (hereinafter referred to as the "Notice")
.
The "Notice" stated that 16 batches of drugs including compound clotrimazole cream produced by 14 companies including Hebei Jiuzheng Pharmaceutical Co.
, Ltd.
were not in compliance with the regulations after being inspected by 8 drug inspection institutions including Anhui Food and Drug Inspection and Research Institute.
.
The relevant situation is now announced as follows:
36 of 2021)" (hereinafter referred to as the "Notice")
.
The "Notice" stated that 16 batches of drugs including compound clotrimazole cream produced by 14 companies including Hebei Jiuzheng Pharmaceutical Co.
, Ltd.
were not in compliance with the regulations after being inspected by 8 drug inspection institutions including Anhui Food and Drug Inspection and Research Institute.
.
The relevant situation is now announced as follows:
After inspection by Anhui Food and Drug Inspection and Research Institute, it was labeled as 1 batch of compound clotrimazole cream produced by Hebei Jiuzheng Pharmaceutical Co.
, Ltd.
which did not meet the requirements, and the non-compliant items were microbiological limits; labeled as Shandong Boshan Pharmaceutical Co.
, Ltd.
One batch of compound clotrimazole cream produced does not meet the regulations, and the items that do not meet the regulations are the filling quantity
.
Medicine, medicine, medicine, Ltd.
which did not meet the requirements, and the non-compliant items were microbiological limits; labeled as Shandong Boshan Pharmaceutical Co.
, Ltd.
One batch of compound clotrimazole cream produced does not meet the regulations, and the items that do not meet the regulations are the filling quantity
.
After inspection by Shanxi Provincial Food and Drug Inspection Institute, it is indicated that the entrusting party is Shanxi Tianzhi Pharmaceutical Co.
, Ltd.
, and the trustee is Chongqing Tianzhi Pharmaceutical Co.
, Ltd.
The first batch of Gucining capsules does not meet the requirements, and the non-compliant items are moisture
.
, Ltd.
, and the trustee is Chongqing Tianzhi Pharmaceutical Co.
, Ltd.
The first batch of Gucining capsules does not meet the requirements, and the non-compliant items are moisture
.
After inspection by Yunnan Food and Drug Supervision and Inspection Institute, the three batches of joint pain relief ointment produced by Jiangsu Baiyi Pharmaceutical Co.
, Ltd.
and Jiangxi Ji'an Sanli Pharmaceutical Co.
, Ltd.
were not in compliance with the regulations, and the items that did not meet the regulations were content determination
.
, Ltd.
and Jiangxi Ji'an Sanli Pharmaceutical Co.
, Ltd.
were not in compliance with the regulations, and the items that did not meet the regulations were content determination
.
A batch of Huanglian Shangqing Pills produced by Sichuan Qiyun Pharmaceutical Co.
, Ltd.
was not in compliance with the regulations after inspection by the Hunan Institute of Drug Inspection (Hunan Pharmaceutical Excipients Inspection and Testing Center)
.
The items that did not meet the regulations were the difference in filling quantity .
Accessories Accessories Accessories, Ltd.
was not in compliance with the regulations after inspection by the Hunan Institute of Drug Inspection (Hunan Pharmaceutical Excipients Inspection and Testing Center)
.
The items that did not meet the regulations were the difference in filling quantity .
After inspection by the Tibet Autonomous Region Food and Drug Inspection and Research Institute, a batch of Keteling capsules produced by Yili Pharmaceutical Co.
, Ltd.
were not in compliance with the regulations, and the non-compliance items were microbiological limits
.
, Ltd.
were not in compliance with the regulations, and the non-compliance items were microbiological limits
.
After inspection by Wuhan Institute of Drug and Medical Device Inspection, a batch of Jiawei Huoxiang Zhengqi Pills produced by Guangzhou Yuehua Pharmaceutical Co.
, Ltd.
is not in compliance with the regulations, and the items that do not meet the regulations are identified
.
Medical equipment medical equipment medical equipment, Ltd.
is not in compliance with the regulations, and the items that do not meet the regulations are identified
.
After inspection by China National Institute for Food and Drug Control, the three batches of argentea produced by Anhui Jiancheng Chinese Medicine Decoction Pieces Co.
, Ltd.
, Anhui Xintai Pharmaceutical Co.
, Ltd.
, and Chengdu Ji'ankang Pharmaceutical Co.
, Ltd.
did not meet the requirements and did not meet the requirements.
For traits
.
, Ltd.
, Anhui Xintai Pharmaceutical Co.
, Ltd.
, and Chengdu Ji'ankang Pharmaceutical Co.
, Ltd.
did not meet the requirements and did not meet the requirements.
For traits
.
According to the inspection by Gansu Provincial Institute of Drug Inspection, the 2 batches of Bupleurum spp.
produced by Chongqing Zhongmiao Pharmaceutical Co.
, Ltd.
are not in compliance with the regulations, and the non-compliance items are traits; and the batch is labeled as 1 batch produced by Guangxi Yulin Tailong Chinese Medicine Decoction Pieces Co.
Sub-Bupleurum (North Bupleurum) does not meet the requirements, and the items that do not meet the requirements are traits; a batch of Bupleurum (North Bupleurum) labeled as Sichuan Renhe Chinese Medicine Decoction Pieces Co.
, Ltd.
does not meet the requirements, and the items that do not meet the requirements are impurities
.
produced by Chongqing Zhongmiao Pharmaceutical Co.
, Ltd.
are not in compliance with the regulations, and the non-compliance items are traits; and the batch is labeled as 1 batch produced by Guangxi Yulin Tailong Chinese Medicine Decoction Pieces Co.
Sub-Bupleurum (North Bupleurum) does not meet the requirements, and the items that do not meet the requirements are traits; a batch of Bupleurum (North Bupleurum) labeled as Sichuan Renhe Chinese Medicine Decoction Pieces Co.
, Ltd.
does not meet the requirements, and the items that do not meet the requirements are impurities
.
The "Notice" stated that for the above-mentioned non-compliant drugs, the drug supervision and administration department has required relevant enterprises and units to take risk control measures such as suspension of sales and use, recalls, and investigations into the reasons for non-compliance and effective rectification
.
Enterprise business enterprise.
State Drug Administration asked the relevant provincial drug administration department according to "People's Republic of China Drug Administration Law", the organization of these enterprises and units of production and sales of fake medicines of inferior quality products illegal investigation, the results of the investigation public in accordance with regulations
.
Inferior MedicineInferior MedicineInferior MedicineInferior Medicine .
